Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Aurélien Marabelle

Showing results (1-10 of 185) with videos related to

Pageof 19
Sort By:
European Journal of Cancer (Oxford, England : 1990)|April 8, 2017
iRECIST: A clarification of tumour response assessment in the immunotherapy eraCharles Ferté, Aurélien Marabelle
European Journal of Cancer (Oxford, England : 1990)|November 29, 2015
How should we use anti-CTLA-4 antibodies?Aurélien Marabelle, Alexander Eggermont
Bulletin Du Cancer|January 1, 2019
Audrey Simonaggio, Aurélien Marabelle
Blood|December 1, 2012
Immunobiology. Combined targeted and immunotherapy: the future of personalized medicineAurélien Marabelle, Christophe Caux
Pediatric Blood & Cancer|March 27, 2015
Tumor-targeted and immune-targeted monoclonal antibodies: Going from passive to active immunotherapyAurélien Marabelle, Juliet Gray
European Journal of Cancer (Oxford, England : 1990)|January 14, 2020
Hyperprogression upon immunotherapy: A chance for (hyper-)progressRoch Houot, Aurélien Marabelle, Stéphane Champiat
JAMA Dermatology|November 24, 2017
Hair Repigmentation With Anti-PD-1 and Anti-PD-L1 Immunotherapy: A Novel HypothesisGuillaume Manson, Aurélien Marabelle, Roch Houot
Cancer Discovery|August 5, 2020
Pegylated Engineered IL2 plus Anti-PD-1 Monoclonal Antibody: The Nectar Comes from the CombinationMathieu Rouanne, Laurence Zitvogel, Aurélien Marabelle
Oncoimmunology|January 23, 2015
New insights into the mechanism of action of immune checkpoint antibodiesAurélien Marabelle, Holbrook Kohrt, Ronald Levy
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 23, 2013
Intratumoral anti-CTLA-4 therapy: enhancing efficacy while avoiding toxicityAurélien Marabelle, Holbrook Kohrt, Ronald Levy
Pageof 19

Showing results (1-10 of 185) with videos related to

Sort By:
Pageof 19
European Journal of Cancer (Oxford, England : 1990)|April 8, 2017
iRECIST: A clarification of tumour response assessment in the immunotherapy eraCharles Ferté, Aurélien Marabelle
European Journal of Cancer (Oxford, England : 1990)|November 29, 2015
How should we use anti-CTLA-4 antibodies?Aurélien Marabelle, Alexander Eggermont
Bulletin Du Cancer|January 1, 2019
Audrey Simonaggio, Aurélien Marabelle
Blood|December 1, 2012
Immunobiology. Combined targeted and immunotherapy: the future of personalized medicineAurélien Marabelle, Christophe Caux
Pediatric Blood & Cancer|March 27, 2015
Tumor-targeted and immune-targeted monoclonal antibodies: Going from passive to active immunotherapyAurélien Marabelle, Juliet Gray
European Journal of Cancer (Oxford, England : 1990)|January 14, 2020
Hyperprogression upon immunotherapy: A chance for (hyper-)progressRoch Houot, Aurélien Marabelle, Stéphane Champiat
JAMA Dermatology|November 24, 2017
Hair Repigmentation With Anti-PD-1 and Anti-PD-L1 Immunotherapy: A Novel HypothesisGuillaume Manson, Aurélien Marabelle, Roch Houot
Cancer Discovery|August 5, 2020
Pegylated Engineered IL2 plus Anti-PD-1 Monoclonal Antibody: The Nectar Comes from the CombinationMathieu Rouanne, Laurence Zitvogel, Aurélien Marabelle
Oncoimmunology|January 23, 2015
New insights into the mechanism of action of immune checkpoint antibodiesAurélien Marabelle, Holbrook Kohrt, Ronald Levy
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 23, 2013
Intratumoral anti-CTLA-4 therapy: enhancing efficacy while avoiding toxicityAurélien Marabelle, Holbrook Kohrt, Ronald Levy
Pageof 19